The FDA expanded use of Temodar to include two new indications for the treatment of adults with anaplastic astrocytoma.

Read about this NEW Clinical Trial and review the eligibility guidelines! "The Ivy Brain Tumor Center at Barrow Neurological Institute is conducting a Phase 1/2 study of sonodynamic therapy (SDT) in patients with recurrent glioblastoma (rGBM).

Scientists at Brigham and Women’s Hospital are harnessing a new way to turn cancer cells into potent, anti-cancer agents. Khalid Shah and his team have developed a new cancer-killing vaccine that can be used to treat existing tumors and prevent recurrences.

To advance our mission of education and advocacy, we have developed a mobile app where you can find information and interact with the Brain Tumor Community. Download the app today.

Meet the Mission Team behind our Programs that deliver our Mission and Advocacy efforts!

Dellann Elliott Mydland, President & Board Chair, End Brain Cancer Initiative (EBCI), is a dynamic competitor due to her experience taking down brain tumors, brain cancer, and metastasized disease to the brain. Read her new article in The Corporate Magazine.

This month’s CURE MAG Cover Tip brought to you by the End Brain Cancer Initiative,  and through our patient advocacy and disease education partnership with CURE, focuses on Glioblastoma Multiforme (GBM).

Navigating care for patients with cancer can be overwhelming considering the multiple specialists they encounter and the numerous decisions they must make. For patients with GBM management is further complicated by a poor prognosis, feelings of isolation, urgency to treat, and cognitive decline.

Exciting news from Corporate Partner GT Medical who offer a truly groundbreaking treatment for those undergoing surgery for their brain tumor in the form of safe and effective surgically targeted radiation delivered right to the tumor site.

Groundbreaking news in the battle against brain cancer.It’s a response-prediction test which improves outcomes by testing live cancer cells against a number of potential therapies to demonstrate which ones will be most effective in killing the tumor cells.

One of my most favorite things to do under my leadership of the EndBrainCancer Initiative is to talk directly to patients with brain cancer and to hear first hand, “their story” and to “see” with my own eyes as well as to “hear” with my own ears how they IMPACT others.

Today, May 31, 2020, the very last day of #BTAM month, I find myself reflecting on many things and just looked through the photos from last year’s Bellingham Brain Cancer WALK (BBCW), and am smiling and crying at the same time.